Vanguard Group Inc Dia Medica Therapeutics Inc. Transaction History

Vanguard Group Inc

$5.97 Trillion
Q2 2025

A detailed history of Vanguard Group Inc transactions in Dia Medica Therapeutics Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,535,054 shares of DMAC stock, worth $10.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,535,054

Previous 1,351,467 13.58%

Holding current value

$10.9 Million

Previous $5.12 Million 16.87%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 11, 2025	BUY	$3.38 - $4.64 $620,524 - $851,843	183,587 Added 13.58%	1,535,054 $5.99 Million
Q1 2025 May 09, 2025	BUY	$3.79 - $6.65 $414,474 - $727,244	109,360 Added 8.8%	1,351,467 $5.12 Million
Q4 2024 Feb 11, 2025	BUY	$4.01 - $5.45 $774,242 - $1.05 Million	193,078 Added 18.41%	1,242,107 $6.57 Million
Q3 2024 Nov 13, 2024	BUY	$2.8 - $4.49 $88,555 - $142,005	31,627 Added 3.11%	1,049,029 $4.4 Million
Q2 2024 Aug 13, 2024	BUY	$2.16 - $3.66 $8,380 - $14,200	3,880 Added 0.38%	1,017,402 $3 Million
Q1 2024 May 10, 2024	BUY	$2.58 - $3.23 $545,285 - $682,663	211,351 Added 26.35%	1,013,522 $2.81 Million
Q4 2023 Feb 14, 2024	BUY	$2.05 - $2.99 $27,433 - $40,012	13,382 Added 1.7%	802,171 $2.28 Million
Q3 2023 Nov 14, 2023	BUY	$2.56 - $4.4 $14,848 - $25,520	5,800 Added 0.74%	788,789 $2.04 Million
Q4 2022 Feb 10, 2023	BUY	$1.13 - $1.62 $394 - $565	349 Added 0.04%	782,989 $1.24 Million
Q1 2022 May 13, 2022	SELL	$2.29 - $3.88 $8,958 - $15,178	-3,912 Reduced 0.5%	782,640 $1.96 Million
Q4 2021 Feb 14, 2022	SELL	$3.43 - $4.65 $3,375 - $4,575	-984 Reduced 0.12%	786,552 $2.93 Million
Q3 2021 Nov 12, 2021	BUY	$3.1 - $4.32 $3,937 - $5,486	1,270 Added 0.16%	787,536 $3.16 Million
Q2 2021 Aug 13, 2021	BUY	$4.45 - $9.91 $3.5 Million - $7.79 Million	786,266 New	786,266 $3.5 Million

Others Institutions Holding DMAC

# of Institutions

Shares Held

6.12M

Call Options Held

Put Options Held

View Full List

About DiaMedica Therapeutics Inc.

Ticker DMAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,443,100
Market Cap $188M
Description
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...

More about DMAC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Dia Medica Therapeutics Inc. Transaction History